Liquidia Corporation (LQDA) Q2 2026 Earnings Call Summary

1Key Financial Results and Metrics

Net Product Sales: YUTREPIA generated $170.4 million in net sales for Q2 2026, marking a 31% increase from the previous quarter.

Net Income: Increased to approximately $74.7 million.

Non-GAAP Adjusted EBITDA: Rose to approximately $96.3 million.

Cash Position: Liquidia ended the quarter with $284.2 million in cash and cash equivalents, up $61.4 million from Q1 2026.

Profitability: The company reported four consecutive quarters of increasing profitability, transitioning from a net loss in Q2 2025.

2Strategic Updates and Business Highlights

YUTREPIA Performance: Over 5,900 unique patient prescriptions and more than 5,000 patients started on therapy since launch. YUTREPIA now accounts for nearly 30% of the inhaled treprostinil market.

Market Growth: The inhaled prostacyclin market grew from $573 million in Q1 to $607 million in Q2 2026, with YUTREPIA's growth surpassing the overall market growth.

Pipeline Development: Liquidia is advancing its pipeline with 10 clinical studies planned or underway for YUTREPIA and L606, aimed at expanding indications and improving patient outcomes.

Sales Force Expansion: The company expanded its sales team in June 2026 to deepen relationships with existing prescribers and penetrate community settings.

3Forward Guidance and Outlook

Revenue Projections: Liquidia is confident in achieving over $1 billion in net revenue by 2027, supported by ongoing growth in YUTREPIA sales and a robust pipeline.

R&D and SG&A Expenses: Expect R&D expenses to double in the second half of 2026 as enrollment ramps up in ongoing studies, while SG&A will increase in line with revenue growth.

4Bad News, Challenges, or Points of Concern

Dosing Regimen: YUTREPIA requires a four-times daily dosing regimen, which may impact patient adherence.

Competitive Landscape: While YUTREPIA is gaining market share, there are concerns regarding competition from other inhaled and oral prostacyclins, particularly as the market evolves.

Regulatory Path for New Indications: The development and regulatory path for expanding YUTREPIA's usage to conditions like IPF and PPF are still being defined, which presents uncertainty.

5Notable Q&A Insights

Patient Growth: The company is experiencing a linear trajectory of new patient starts, with confidence in maintaining this growth through community penetration and increased sales force activity.

Pharmacist Engagement: The role of pharmacists in supporting PAH patients is critical, and Liquidia is focusing on educating them about YUTREPIA's benefits.

Market Dynamics: The company noted that the hemodynamic definition of pulmonary hypertension has changed, potentially increasing the diagnosed patient population and market opportunity.

Legal Matters: Ongoing litigation remains a concern, with outcomes uncertain but management expressing confidence in their legal position. Overall, Liquidia Corporation reported strong financial results and strategic progress, particularly with YUTREPIA, while also acknowledging competitive pressures and the need for ongoing investment in R&D and sales efforts.